Research Article
Evaluation of Plasma Total Antioxidant Response and Total Peroxides in Different Symptoms of Schizophrenia Patients

P. Uma Devi, D. Devipriya, S. Murugan, S. Selvi, S. Suja and P Chinnaswamy

International Journal of Biological Chemistry, 2008, 2(1), 26-34.


This study aims to measure Total Antioxidant Capacity (TAC) and Total Peroxides (TP) in schizophrenia patients with positive, negative and cognitive symptoms using Ferric Reducing Activity of Plasma (FRAP) and evaluate its relations with oxidative stress. We measured the plasma total antioxidant potential and total peroxides in 60 schizophrenia patients and in 60 well-matched non-schizophrenic control subjects. The association between the total antioxidative-oxidative potential and the symptoms, severity of schizophrenia were studied. Total antioxidant capacity/total peroxide of the clinical samples was measured using latest spectrophotometric measurement method. Results showed that plasma TAC was found to be lower in patients with schizophrenia than those of controls. On the contrary, the patients had high total plasma peroxide levels. Oxidative Stress Index (OSI) values of the patients were significantly higher than those of controls (p<0.001). Plasma TAC of each schizophrenia symptoms were significantly lower than healthy controls (p<0.01 for patients with negative and cognitive symptoms and p<0.001 for patients with positive symptoms). When intragroup comparisons were performed, patients with positive symptoms had significantly very low plasma TAC levels (p<0.001) compared to other negative (p<0.01) and cognitive subtypes (p<0.01). Plasma TAC in schizophrenia patients was significantly and inversely correlated with symptom severity. This study indicates that schizophrenia is associated with increased oxidative stress, depleted antioxidant status in schizophrenia subjects and supplementation with more antioxidative supplements could be considered in treatment.

ASCI-ID: 34-6

Statistical Analysis
Results were expressed as mean±standard deviation. Differences were considered significant at a probability level of p<0.05. Obtained results were evaluated by repeated measurement variance analysis. Correlation analysis was done between TP, TAC and OSI.


A total of 60 schizophrenia patients and 60 non-schizophrenia subjects were recruited. Table 1 shows the total antioxidant capacity of schizophrenia subjects with positive, negative and cognitive symptoms.

TAC level was 0.976±0.44, 1.36±0.52, 1.42±0.43 and 1.99±0.47 mmol Trolox eq. L-1 in the positive, negative, cognitive symptoms of schizophrenia groups and in the control group, respectively; TP level was 19.63±1.39, 17.21±1.67, 18.021±1.32 and 13.95±1.79 μmol H2O2 L-1 in the same study groups and in the control group, respectively; OSI values were 1.95±1.89, 1.34±2.98, 1.16±0.87 and 0.61±1.45 arbitrary Units in the positive, negative and cognitive group and in the control group, respectively. The comparison between the schizophrenia group and the control group revealed that the level of TAR was significantly lower and TP and OSI levels were significantly higher in all the study groups (p<0.01), but these changes were statistically more significant in the study group with positive symptoms (p<0.001).

The values of TAR in chronic patients(0.92±0.43 mmol Trolox eq. L-1) were significantly lower compared to acute patients (1.23±0.47 mmol Trolox eq. L-1) (p<0.01). The mean (±SD) levels of TP and OSI in acute patients were significantly lower (16.13±1.47 μmol H2O2 L-1 and 1.41±2.12) compared to chronic patients (18.78±1.49 μmol H2O2 L-1 and 2.34±0.72) at p<0.01 (Table 2).

Correlation analysis were performed and are shown in Fig. 1. Figure 1a shows the correlation between TP and TAC of type: 1 (Schizophrenic with positive Symptoms). Here the total peroxides formed and total antioxidant capacity are par with each other indicating that peroxides produced are scavenged by the antioxidant systems. In the case of type 2 (Schizophrenic with Negative symptoms) (Fig. 1b), there was a linear increase in total peroxides and total antioxidant capacity (r = 0.945). But in type 3 (schizophrenics with cognitive symptoms) (Fig. 1c) a negative correlation was obtained (r = -0.763) indicating the increase in oxidative stress Similar observations were seen while relating the total antioxidant capacity and oxidative stress (Fig. 1e-h).

Table 1: Circulatory levels of a. TAC, TP and OSI in schizophrenia patients with different symptoms and healthy control groups
Type 1: Schizophrenic with positive Symptoms; Type 2: Schizophrenic with Negative symptoms; Type 3: Schizophrenic with cognitive symptoms, a b c and d p<0.01 ; a* p<0.001, a: Statistical significance compared to control group; b: Statistical difference between positive and negative group; c: Statistical difference between positive and cognitive group; d: Statistical difference between negative and cognitive group

Table 2: Plasma levels of TAR, TP and OSI in acute and chronic Schizophrenia patients (Values are mean±SD)
Statistical comparison was done between acute and chronic Schizophrenics *: p<0.001

Fig. 1: (a) Correlation between TP and TAC (type 1), (b) Correlation between TP and TAC (type 2), (c) Correlation between TP and TAC (type 3), (d) Correlation between TP and TAC control), (e) Correlation between TAC and OSI (type 1), (f) Correlation between TAC and OSI (type 2), (g) Correlation between TAC and OSI (type 3) and (h) correlation between TAC and OSI (control)


There is a large amount of convincing data demonstrating that Reactive Oxygen Species (ROS) are involved in initiation and development of many different forms of schizophrenia. The levels of oxidants and antioxidants in schizophrenia have been evaluated. However, measurements of Total Antioxidant Capacity (TAC) and total peroxides in schizophrenia patients having different symptoms and their severity (acute and chronic phases of the disease) based abnormalities were not evaluated up to date. Therefore, the objectives of this study were to investigate plasma TAC-TP levels in schizophrenia with different symptoms. Our results indicates that the oxidative/ antioxidative balance shifted towards oxidative status, namely increased oxidative stress was present in patients with schizophrenia compared with healthy control subjects.

It was indicated that ROS and other oxidants could be also formed in the normal physiological process (Onder and Gurer, 2001). Increased ROS, in turn, enhance LPO products, thus, lead to tissue injury (Yazici et al., 2004; Onder and Gurer, 2001). H2O2 and other derivatives of peroxides increase in some conditions, diffuse into plasma. Here, antioxidant components of plasma overwhelm them and they are simultaneously consumed (Young and Woodside, 2001; Murat et al., 2002).

When TP is measured, it means that the sum of many peroxides like protein peroxide, lipid peroxide and H2O2 are measured (Abuja and Albertini, 2001). Although it is known that H2O2 and lipid peroxides increase in schizophrenia (Herken et al., 2001; Dusica and Vesna, 2002; Hui-chun et al., 2006; Dadheech et al., 2006; Surapareni, 2007), oxidative stress has not been evaluated through TP-TAC in schizophrenia. It has been reported by Ustundag et al. (2002) that TAC level decreases in schizophrenia patients and decreased plasma total antioxidant levels may be related to the progression of illness. It was shown in the present study that TAC level also decreased in schizophrenia patients compared with control subjects.

It was observed in our study, among patients with different symptoms, there was a statistically more significant decrease was found in the level of TAC in patients with positive symptoms (p<0.001). It was clear from the results that there was no significant difference in the levels of TAC and TP between negative and cognitive symptomatic people, though the levels differed from the control subjects. Possible reasons for this increase in TP might be the inevitable increase in lipid peroxides and ROS including H2O2 in schizophrenia. Many antioxidant molecules found in blood prevent or inhibit the harmful effects of free radicals (Young and Woodside, 2001). Whenever there is a decrease in antioxidants and/or an increase in oxidants, oxidant/antioxidant balance is impaired in favor of oxidants and this is known as oxidative stress (Abuja and Albertini, 2001; Ghiselli et al., 2000). It is known that oxidative stress is responsible for tissue injury in many diseases and contributes to the development of schizophrenia (Granot and Kohen, 2004). Antioxidant activity indicates the antioxidant characteristics of only one antioxidant, whereas TAC represents the total antioxidant characteristics of all antioxidants found in the plasma. TAR and Total Antioxidant Status (TAS) are used synonymously with TAC (Ghiselli et al., 2000). It is doubtlessly more advantageous to evaluate TAR, instead of individual antioxidant activities. Since it has been reported that TAR, a new measurement method developed by Erel, correlated with data obtained by other measurement methods and has had some extra advantages (Erel, 2004a, b), we followed this method in our study.

Ustundag et al. (2002) have reported a decrease in TAR level in schizophrenia patients. Similarly, TAR level was found low in the study groups in the present study. A negative correlation (r = -0.763) existed between TP and TAC in Type 3 and also in control(r = -0.196) but not to the level as seen in Type 3. Type 3 also showed a negative correlation in TAR and OSI (r = -0.866). The other groups Type 1, 2 and control a positive correlation was obtained when correlations between TP and TAC and TAC and OSI were done indicating that the subjects were able to mitigate the oxidative stress developed. The increase in TP and OSI levels and the tion between these increases and TAC level in the present study suggest that a possible cause of the decrease in TAC level may be increased oxidative stress. The decrease in TAR is not possible to attribute to only one of the individual antioxidants. Therefore, the decrease in TAC must have resulted from the decrease in combination of many antioxidants. In the light of these data, a possible reason for the decrease in TAR in schizophrenia may be the decrease in other antioxidants, like enzymic and non enzymic antioxidants. As TAR is a fairly good representative of antioxidant capacity and TP and OSI are representatives of oxidant capacity, decreased TAC and/or increased TP levels indicate oxidative stress (Erel, 2004a, b; Ghiselli et al., 2000; Yanik et al., 2004). In the present study, there was a significant decrease in TAR level and an increase in TP and OSI levels in the study groups. Based on our results, it is necessary to consider the fact that increased ROS and LPO products as a result of neurodegeneration can be responsible for the impairment in oxidant/antioxidant balance, the increase in ROS and LPO products and the decrease in antioxidant capacity are expected to be more marked in the positive group (p<0.001) in comparison to the negative and cognitive groups (p<0.01). By our study, it is also possible that the oxidant/antioxidant balance is impaired at the onset of the disease and continues In conclusion, TAR is an appropriate measurement method demonstrating oxidant/antioxidant balance. Oxidant/antioxidant balance seems to be impaired at all stages and symptoms of schizophrenia. Further the impairment was more pronounced in patients with positive symptoms, elderly patients and male schizophrenia patients. In future, wethink that this argument should be confirmed by controlled, multi-centered, prospective studies, which shall include large case series and employ reviewed disease activity criteria.

TAC of plasma was significantly lower in chronic patients with schizophrenia than in acute schizophrenia patients. In contrast, mean (SD) total peroxide level of plasma was significantly higher in the chronic patients than in acute subjects. The mean oxidative stress index level was significantly higher in chronic schizophrenia patients than in acute age and gender matched schizophrenia patients [2.34±0.72 versus 1.41±2.12, respectively (p<0.001)]. Our results were consistent with the results of Dadheech et al. (2006), who postulated that the levels of antioxidants in chronic schizophrenia patients showed a decrease as compared to acute attributed to the antioxidant deficit due to chronic phase of schizophrenia. Our results also supports Ustundag et al. (2002) who pointed out that duration of schizophrenia is directly correlated with decreased plasma total antioxidants levels.

We hypothesize that oxidant stress increases in chronic phase of schizophrenia and oxidant defense systems weaken during the chronic course of the illness. Due to decreased antioxidant potential, which probably lengthens the continuous peroxides exposure and decreases the sensitivity to oxidation appears to be lower in schizophrenia patients. The patients with schizophrenia are exposed to oxidative stress and OSI may be useful to reflect the severity of the disease


Based on the presented data, free radicals and impaired antioxidants play an important role in the functioning of the brain and schizophrenia patients with positive symptoms and chronic schizophrenia patients are having more oxidative stress compared with patients having other symptoms and acute stage of illness. Until now we have not found univocal molecular basis of schizophrenia which might be due to free radicals. Further studies comprise of more number of patients are needed to explain and confirm the exact mechanisms of oxidative stress in patients with different symptoms of schizophrenia. Research concerning free radicals and antioxidative enzymes activities and supplementation with antioxidative supplements might prevent and treat schizophrenia.


The authors are grateful to Dr. Nalla, G. Palanisamy, M.B.B.S., MD, the Chairman and Dr. Thavamani D. Palanisamy, M.B.B.S., DCH, the secretary, Kovai medical center and hospitals and Dr. N.G.P. Arts and Science College, Coimbatore, India, for providing encouragement and technical support to carry out this project." class="btn btn-success" target="_blank">View Fulltext

Cited By

Oxidative stress indices in ASD children in Sub-Sahara Africa

Journal of Neurodevelopmental Disorders, 2021, 13(1), . DOI: 10.1186/s11689-021-09379-w